A descriptive single-centre experience of the management and outcome of maternal alloantibodies in pregnancy.

This study demonstrates that morbidity and mortality caused by HDFN is minimal. These results are reassuring for women at risk of HDFN as even severely affected cases are successfully managed in most instances. Further studies are needed to identify predictors of disease severity.